Ham­mered by a se­ries of set­backs, NewLink ax­es staff (again) and cir­cles its wag­ons around trou­bled IDO pro­gram

Three months af­ter NewLink Ge­net­ics scrapped a com­bi­na­tion pro­gram for its IDO path­way drug in­dox­i­mod in the gen­er­al rout that fol­lowed the fail­ure of In­cyte’s big IDO project for epaca­do­stat, the biotech is nev­er­the­less cir­cling its wag­ons around a last stand ef­fort to prove their ther­a­py can work and make it to the mar­ket. In the process, the Iowa-based com­pa­ny has slashed close to a third of its staff and re­or­ga­nized the C suite in the process.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.